Alpha 2.0
Login Register
» Authors » J L Vizmanos

J L Vizmanos

Explore the profile of J L Vizmanos including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 80
Followers 0
Related Specialties
Hematology
Oncology
General Medicine
Top 10 Co-Authors
F J Novo
M Garcia-Delgado
M J Calasanz
N C P Cross
M J Larrayoz
P Aranaz
A Gullon
X Agirre
J Prieto
M D Odero
Published In
Leukemia
Rev Neurol
Biotechniques
Leuk Res
An Sist Sanit Navar
Affiliations
Soon will be listed here.
Recent Articles
1.
Constitutional genetic association with CALR mutations?
Eder-Azanza L, Evans P, Wickham C, Akiki S, Vizmanos J, Chase A, et al.
Leukemia . 2015 Jul; 29(12):2410-1. PMID: 26198293
No abstract available.
2.
Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling
Eder-Azanza L, Navarro D, Aranaz P, Novo F, Cross N, Vizmanos J
Leukemia . 2014 Jun; 28(10):2106-9. PMID: 24919806
No abstract available.
3.
LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation
Hurtado C, Erquiaga I, Aranaz P, Migueliz I, Garcia-Delgado M, Novo F, et al.
Leuk Res . 2011 Jul; 35(11):1537-9. PMID: 21794913
No abstract available.
4.
Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs
Ormazabal C, Hurtado C, Aranaz P, Erquiaga I, Garcia-Delgado M, Calasanz M, et al.
Leuk Res . 2008 Feb; 32(9):1485-7. PMID: 18291525
No abstract available.
5.
JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients
Vizmanos J, Ormazabal C, Larrayoz M, Cross N, Calasanz M
Leukemia . 2006 Jan; 20(3):534-5. PMID: 16408096
No abstract available.
6.
Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies
Odero M, Grand F, Iqbal S, Ross F, Roman J, Vizmanos J, et al.
Leukemia . 2004 Dec; 19(2):245-52. PMID: 15618963
Chromosomal translocations that target HMGA2 at chromosome band 12q14 are seen in a variety of malignancies, notably lipoma, pleomorphic salivary adenoma and uterine leiomyoma. Although some HMGA2 fusion genes have...
7.
Cryptic ins(2;11) with clonal evolution showing amplification of 11q23-q25 either on hsr(11) or on dmin, in a patient with AML-M2
Vazquez I, Lahortiga I, Agirre X, Larrayoz M, Vizmanos J, Ardanaz M, et al.
Leukemia . 2004 Oct; 18(12):2041-4. PMID: 15483676
No abstract available.
8.
[Genetic alterations in hematological neoplasias of lymphoid origin: implications for clinical practice]
Vizmanos J, Agirre X, Calasanz M, Garcia M, Novo F
An Sist Sanit Navar . 2003 Jul; 23(3):451-65. PMID: 12886300
The improvement of the conventional cytogenetic techniques, the development of molecular cytogenetics and the application of techniques of molecular biology to genetic analysis have led to an authentic revolution in...
9.
[Prevalence of CYPD6 mutations in sporadic Parkinson's disease: case-control study]
Guerrero D, Garcia-Delgado M, Larumbe R, Vizmanos J, Novo F, Vines J
An Sist Sanit Navar . 2003 Jul; 25(2):147-54. PMID: 12861292
Genetic factors seem to play an important role in the development of Parkinson's disease. The degeneration of the sustantia nigra, characteristic of this disease, might be due to the toxic...
10.
Exon concatenation to increase the efficiency of mutation screening by DGGE
Agirre X, Garcia-Delgado M, Calasanz M, Larrayoz M, Novo F, Vizmanos J
Biotechniques . 2002 May; 32(5):1064-5, 1068-70. PMID: 12019779
For genes that have a substantial number of exons and long intronic sequences, mutation screening by denaturing gradient gel electrophoresis (DGGE) requires the amplification of each exon from genomic DNA...